Drug: Ponatinib (Iclusig, Ariad)
Status: Ponatinib is fully approved to treat adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other tyrosine kinase inhibitor therapy is indicated; and for the treatment of adult patients with T315I-positive CML (chronic phase, accelerated phase or blast phase) or T315I-positive Ph+ ALL.
Significant Data:
- Full approval